MCS110: Clinical Trials

5 trials of MCS110, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated, 1 withdrawn. 5 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Completed 2, Terminated 2, Withdrawn 1
Phase 23Completed 2, Terminated 1

Follow MCS110: new trials by email Literature Review of MCS110 trials Research Report on MCS110

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
spartalizumab, LAG525, NIR178 - Triple Negative Breast Cancer (TNBC)
Phase 1TerminatedNovartis Pharmaceuticals642019-01-312025-05-18
MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
MCS110, Doxorubicin, Cyclophosphamide - Breast Cancer, Cancer of Breast
Phase 1WithdrawnWashington University School of Medicine2018-09-302018-08-16
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
MCS110, Dabrafenib, Trametinib - Melanoma
Phase 1 / Phase 2CompletedDana-Farber Cancer Institute62018-09-102024-07-31
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
MCS110, PDR001 - Triple Negative Breast Cancer, Pancreatic Carcinoma
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals1412016-06-292021-08-11
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
MCS110 - Prostate Cancer, Bone Metastases
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals32008-09-012020-12-19

Conditions studied

Melanoma (2)  ·  Triple Negative Breast Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Endometrial Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Pancreatic Neoplasms (1)  ·  Prostatic Neoplasms (1)

Sponsors

Novartis Pharmaceuticals (3)  ·  Dana-Farber Cancer Institute (1)  ·  Washington University School of Medicine (1)

Countries

United States (4)  ·  Hong Kong (2)  ·  Italy (2)  ·  Japan (2)  ·  Spain (2)  ·  Australia (1)  ·  Belgium (1)  ·  Finland (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Netherlands (1)  ·  Singapore (1)  ·  South Korea (1)  ·  Switzerland (1)

Top investigators

Elizabeth I Buchbinder, MD (1)  ·  Leonel Hernandez-Aya, M.D. (1)

Results publications

PMID 38721402

NIH funding

2016 (1), 2018 (1)